The frequency of Her-2 gene abnormalities in NSCLC is lower than that of EGFR, but its tumour driving mechanism is clear, and it is sensitive to some targeted drugs, making it a current research hotspot. This evidence concerns the gene EGFR and non-small cell lung carcinoma.